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agnosis, duration of disease, clinical and laboratory symptoms, procedures of di-
alysis and antianemic therapy). Health-related quality of life was assessed with
self-administrated validated version of Russian version of Euroqol-5D question-
naire. Inclusion criteria were age older than 18 years, terminal stage of chronic
renal failure and treatment with dialysis more then 4 months. RESULTS: 1395
completed questionnaires were received by September, 2010. Mean age was 42
years. 45% patients reported chronic glomerulonephritis as a main reason of
chronic renal failure, 22% - chronic pyelonephritis, 10% - diabetes, 8% - polycystic
kidney disease, other diseases – 1,5%. Average level of hemoglobin was 10716.2
g/l. 80% of patients reported that they got 12-14 procedures of dialysis during last
month. The average length of one procedure was 4-5 hours just for 17% of patients,
in other cases (80%) length of dialysis was shorter. Analysis of antianemic therapy
has shown that 85% got erytropoetins and 70% - iron supplements. More than half
of patients reported problems within each of EQ-5D dimensions of health. Thus
42.5% of patients reported problems withmobility, 20% - difficulties with self-care;
58.7% - difficulties with usual activities; 67% - reported about pain or discomfort;
47% - reported about an anxiety or depression. The average value of quality of life
evaluated with visual-analog scale (VAS) was 0.59 (SD 0.17), median – 0.6.
CONCLUSIONS:Analyses of quality of life have demonstrated high rate of problem
with usual activity and pain and discomfort and low rate of problem with self-
service.
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OBJECTIVES: To assess health status, treatment patterns and quality of life in
patients with hereditary coagulopathies in Ukraine.METHODS: Postal health sur-
vey. Questionnaires were distributed in May - August 2009. Health-related quality
of life was assessedwith self-administrated validated version of Russian version of
Euroqol-5D questionnaire. Comparison was made with data about health-related
quality of life of Russian patients (P.Vorobeyv et. al., 2008, data of 1003 patients was
used in analyses). Analysis of experimental data was performed with 2 criteria.
RESULTS: 154 completed questionnaires were received by September, 2009.
Health-related quality of lifewas assessed for patients older than 11 years (n 142).
More than half of patients reported problems within each of EQ-5D dimensions of
health. Thus 88.8% of patients reported of problems (moderate and severe) with
mobility (63.9% of Russian patients, p0.05), 57.7% of patients inform of difficulties
with self-care (35.5% of Russian patients, p0.05); 81% of patients had difficulties
with usual activity (61.9% of Russian patients, p0.05); 90.9% of patients reported of
presence of pain/discomfort (78.9% of Russian patients, p0.05); 60.5% of patients
had an anxiety or depression (54.2% of Russian patients, p0.05). The average value
of quality of life according to visual-analog scalewas 0.44 (SD 0.22). CONCLUSIONS:
The study of quality of life in patients with hereditary coagulopathies was per-
formed for the first time in Ukraine. Results of the study shown high rate of prob-
lems all aspects of health-related quality of life. Ukraine patients with hemophilia
have worse quality of life than Russian patients.
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OBJECTIVES: The fight against pain, which represents a public health challenge
and a criteria of the quality and development of a health system, above all aspires
tomeet objectives of humanity, ethics and human dignity. Physical pain andmen-
tal suffering experienced across all age groups renders those affected by illness
even more vulnerable. Pain causes incapacity, handicap and considerable deterio-
ration in the quality of life. Fighting against pain meets a legitimate expectation of
every person. METHODS: To assess the quality of life in patients suffering from
intense pain which has progressed since less than 7 days treated by a combination
of paracetamol and codeine. Amulti-centre longitudinal observational prospective
study carried out in metropolitan France using data collected by general practitio-
ners who agreed to participate. RESULTS: 574 patients treated by a paracetamol-
codeine combination (600mg/50mg and 400mg/20mg) were included; at inclusion
the quality of life assessed using SF-12was affected asmuch in terms of themental
component (41.83  7.92) as the physical component (35.88  11.68) – the norm of
the scores for each component is equal to 50 – on D7, the quality of life assessed in
a similarmanner using SF-12 was 43.31 9.89 for themental component and 40.93
7.92 for the physical component. A statistically significant improvementwas noted
for each of the 2 mental (p0.0091) and physical (p0.0001) components between
the first day of treatment and the 7th day. CONCLUSIONS: The improvement in
quality of life observed directly through SF-12 was also confirmed by patient satis-
faction: from the first day, 61% of patients declared themselves to be satisfied. On
the 7th day of treatment, 87.10% were satisfied with their treatment.
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OBJECTIVES: Congenital hemophilia is a chronic disease diagnosed early in life in
severe cases. Development of alloantibody inhibitors to exposure to replacement
factor VIII and IX concentrates is the most serious treatment complication among
patients. It is estimated that 900-1,200 patients have congenital hemophilia with
inhibitors (CHwI) in theUnited States (US). Limited research exists to document the
experience of their caregivers.METHODS: As part of a cross-sectional survey eval-
uating preservation of joint health and quality of life among CHwI patients in the
US, caregivers’ experience was assessed via the HAEMO-QoL instrument, contain-
ing an open-ended question capturing caregivers’ burden. Responses were as-
sessed for trends and consolidated into categories. Descriptive analyses were em-
ployed to evaluate caregivers’ demographic characteristics and their burden with
the disease. RESULTS: Questionnaires were received from 60 caregivers. Mean age
of patients under care was 10.6 years (SD10.3). 91.7% of patients under care had
Hemophilia A and 68.3% had high-titer inhibitors. Unemployment as a result of
caregiver responsibilities was reported by 28.1%. 31.7% reported having health
insurance with a lifetime cap. Among these, 73.7% were “somewhat” to “very con-
cerned” about reaching the cap. Among 55 HAEMO-QoL respondents 26.3% were
“considerably” to “very much so” bothered by the patient’s disease. A total of 159
open-ended responses were provided by 51 caregivers concerning their experience
about living with hemophilia and its treatment: 22.6% highlighted emotional
stress, 15.1% emphasized financial burden includingwork time, 12.0% involved lost
time excluding work, and 11.3% involved medical management issues.
CONCLUSIONS: One quarter of caregivers were “considerably” to “very much”
bothered by the patient’s condition. They reported emotional stress and financial
burden as negative experiences dealing with hemophilia and its treatment. Medi-
calmanagement is also an area of concern. A caregiver’s negative experiencemight
impact children’s HRQoL, which should be analyzed in future research.
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OBJECTIVES: The impact of lupus on patients’ everyday lives is important to un-
derstand. We therefore investigated the perceptions of lupus patients on disease
symptoms and coping strategies. METHODS: Participants (USA and Europe) com-
pleted a patient-led Internet-based questionnaire between April and May 2009.
RESULTS: 914 respondents reported having lupus (95% female, 80% 20–50 years of
age). Themost common lupus symptoms reportedwere fatigue (92%) and arthritis,
muscle pain/weakness or tendinitis (89%). Antimalarials were themost commonly
used lupus treatment (53%), followed by corticosteroids (51%). Less than half of the
respondents were satisfied/very satisfied with their current treatment (49%). Ap-
proximately one-third of respondents stated that lupus had a highly significant
effect on their careers (37%), on their physical well-being (34%) and on everyday
things (30%). Furthermore, approximately one-fifth of respondents felt that lupus
had a highly significant effect on their social life (23%) and mental health (20%),
while 11% reported it had a highly significant effect on their relationship with their
family. Most patients reported talking to family (93%) and friends (89%) about lupus
or sharing with them they had lupus (97% and 95%, respectively); 79% reported
talking to others with lupus. 77% reported it was ‘easy/very easy’ to talk to their
doctors about their symptoms. The most difficult symptoms to explain were de-
pression (45%) and CNS problems (34%). The most helpful forms of support were
understanding from family and friends (73%), ability to speak with healthcare pro-
fessionals (63%), and being connected to other lupus patients via the Internet (50%).
CONCLUSIONS: Lupus impacts greatly on patient’s everyday lives with the most
common symptom reported being fatigue. Many patients remain unsatisfied with
their treatment. Communicationwith familymembers, friends, healthcare profes-
sionals and other lupus patients are important strategies to facilitate coping with
lupus symptoms.
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OBJECTIVES: Efficacious medical or behavioral weight-loss programs are not rou-
tinely covered by insurance. Understanding how patients value weight loss inter-
ventions by assessing their willingness to pay (WTP) is critical to translating find-
ings from effectiveness trials into practice. Upon completion of a randomized
clinical trial comparing an in-person behavioral intervention to a phone/email/
web-based intervention for weight-loss, we studied participants’ WTP and charac-
teristics associated with WTP for continuing these programs. METHODS: POWER
Hopkins is an NHLBI-funded 24-month randomized clinical trial of weight loss
comparing in-person vs. call center directed coaching interventions plus web-
based education and tracking support. At the end-of-study visit, we interviewed
participants and used double bound dichotomous-choice to assess their WTP. Us-
ing linear regression, we examined baseline characteristics (age, sex, income, race,
education, and BMI) associated with WTP. RESULTS: Of the 234 adults completing
the trial to date, 206 (88%) reported on WTP. Mean age was 57 years, 61% were
women, 56.3% were White, mean BMI at baseline (2 years earlier) was 36.4 kg/m2,
33% had graduate or professional degrees, 61% had annual family income
$75,000. Participants thought their intervention was worth $70.9 (95%CI 60.3-
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